Rodent models for the preclinical evaluation of drugs suitable for pharmacological intervention in aging

Expert Opinion on Drug Discovery

Volumn 7, Issue 1, 2012, Pages 85-95

  Anisimov, Vladimir N ^a   Zabezhinski, Mark A ^a   Popovich, Irina G ^a   Pliss, Gennady B ^a   Bespalov, Vladimir G ^a   Alexandrov, Valeri A ^a   Stukov, Alexander N ^a   Anikin, Ivan V ^a   Alimova, Irina N ^a   Egormin, Peter A ^a   Panchenko, Andrey V ^a   Piskunova, Tatiana S ^a   Semenchenko, Anna V ^a   Tyndyk, Margarita L ^a   Yurova, Maria N ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

Anticarcinogenic effect and rodents; Antitumor; Life span extension; Pharmacological drugs; Testing

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; AQUALEN; BETA CAROTENE; CYTOFLAVIN; DIABENOL; EMOXIPIN; EPITALON; EPITHALAMIN; GINSENG EXTRACT; LEVODOPA; MELATONIN; METFORMIN; NEURONOL; NICOTINAMIDE; ORTOPHEN; PEPTIDE DERIVATIVE; PHENFORMIN; PHENYTOIN; PIRACETAM; POLYPEPTIDE; PYRIDOXINE; RAPAMYCIN; RIBOFLAVIN DERIVATIVE; RIBOXIN; SUCCINIC ACID; THYMOGEN; TIMALIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILON;

AGING; ANTINEOPLASTIC ACTIVITY; DRUG RESEARCH; DRUG SAFETY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LIFESPAN; NONHUMAN; PREMATURE AGING; PRIORITY JOURNAL; REVIEW; RODENT; STANDARDIZATION;

AGING; ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; LONGEVITY; MICE; RATS;

EID: 84855368515     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.642361     Document Type: Review

References (61)

1. Andrews GR, Sidorenko A, Andrianova LF, et al. The United Nations research agenda on ageing for the 21st century. Adv Gerontol 2001;7:7-25
2. FUTURAGE: A Road Map for European Ageing Research, October 2011. Available from: www.futurage. group.shef.ac.uk/road-map.html
3. Rae MJ, Butler RN, Campisi J, et al. The demographic and biomedical case for late-life interventions in aging. Sci Transl Med 2010;2(1):40cm21
4. Anisimov VN. Molecular and Physiological Mechanisms of Aging. Volume 1 & 2 Nauka; St.Petersburg: 2008
5. Anisimov VN. Life span extension and cancer risk: myths and reality. Exp Gerontol 2001;36:1101-36 (Pubitemid 32515223)
6. Anisimov VN. Premature ageing prevention: limitations and perspectives of pharmacological interventions. Curr Drug Res 2006;7:1485-504
7. Rattan SIS. editor. Aging Interventions and Therapies. World Scientific Publishing Co.Pte.Ltd; New Jersey: 2005
8. Hefti FF, Bales R. Regulatory issues in aging pharmacology. Aging Cell 2006;5:3-8 (Pubitemid 43348956)
9. Kirkland JL, Peterson C. Healthspan, translation, and new outcomes for animal studies of aging. J Gerontol Biol Sci 2009;64A:209-12
10. Spindler SR. Review of the literature and suggestion for the design of rodent survival studies for the identification of compounds that increase health and life span. AGE doi10.1007/s11357-011-224-6
11. Tollefsbol TO. Biological Aging: Methods and Protocols. Humana Press, Totowa,; New Jersey: 2007
12. Khabriev RU. editor. Manual on Experimental (Preclinical) Study of New Pharmacological Compounds. 2nd edition. Meditsina Publ; Moscow: 2005
13. Ingram DK, Jucker M. Developing mouse models of aging: a consideration of strain differences in age-related behavioral and neural parameters. Neur@biol Aging 1999;20:137-45 (Pubitemid 29488724)
14. Maronpot RR, Flake G, Huff J. Relevance of animal carcinogenesis findings to human cancer predictions and prevention. Toxicol Pathol 2004;32(Suppl 1):40-8 (Pubitemid 38437566)
15. Anisimov VN, Ukraintseva SV, Yashin AI. Cancer in rodents: does it tell us about cancer in humans? Nat Rev Cancer 2005;5:807-19 (Pubitemid 41408566)
16. Jackson Laboratories Strain Information. Available from: http:/jaxmice.jax.org. jaxmicedb/html. inbred/shtml
17. Nadon NL. Exploiting the rodent model for studies on the pharmacology of lifespan extension. Aging Cell 2006;5:9-15 (Pubitemid 43348957)
18. Anisimov VN. Spontaneous tumors in rats of various strains. Vopr Onkol 1976;22(8):98-110
19. Anisimov VN. Carcinogenesis and Aging. Volume 1 CRC Press; Boca Raton: 1987
20. Smith GS, Walford RL, Mickey HR. Lifespan and incidence of cancer and other diseases in selected long-lived inbred mice and their F1 hybrids. J Natl Cancer Inst 1973;50:1195-213
21. Ward JM. Background data and variations in tumor rates of control rats and mice. Prog Exp Tumor Res 1983;26:241-58
22. Teicher BA. editor. Tumor Models in Cancer Research. Humana Press; New Jersey: 2003
23. Anisimov VN, Popovich IG, Zabezhinski MA, et al. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim Biophys Acta 2006;1757:573-89
24. Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany, NY) 2010;2:760-74
25. Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 2008;7:2769-73
26. Snyder DL, Pollard M, Wostmann BS, Lackert P. Life span, morphology, and pathology of diet-restricted germ-free and conventional Lobund-Wistar rats. J Gerontol 1990;52:B52-8 (Pubitemid 20104841)
27. Anisimov VN, Popovich IG, Zabezhinski MA. Models and methods of study on geroprotective activity of pharmacological preparations. Adv Gerontol 2009;22:237-52
28. Anisimov VN, Popovich IG, Zabezhinski MA. Methods of evaluating the effect of pharmacological drugs on aging and life span in mice. In: Tollefsbol TO, editor. Biological Aging: Methods and Protocols (Methods in Molecular Biology; volume 371). Humana Press; Totowa, New Jersey: 2007. p. 227-36 (Pubitemid 350183429)
29. Montesano R, Bartsch H, Vainio H, et al. Long-term and short-term assays for carcinogens: a critical appraisal. IARC Sci Publ No 83;; Lyon: 1986
30. Anisimov VN. Aging and cancer in transgenic and mutant mice. Front Biosci 2003;8:S883-902
31. Turusov VS, Parfenov YD. Revealing and specification of chemical carcinogens. Meditsina; Moscow: 1986
32. Smyth RD, Hottendorf GH. Application of pharmacokinetics and biopharmaceutics in design of toxicological studies. Toxicol Appl Phramacol 1980; 53:179-95 (Pubitemid 10021865)
33. Rhomberg LR, Baetcke K, Blancato J, et al. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection. Crit Rev Toxicol 2007;37:729-37
34. Arutjunyan AV, Dubinina EE, Zybina NN. Methods of evaluation of free radical oxidation and of antioxidase system of the organism. Methodical recommnedations. Foliant; St.Petersburg: 2000
35. Rozenfeld SV, Togo EF, Mikheev VM, et al. Age-associated dynamics of chromosome aberration incidence in male mice of different strains. Bull Exp Biol Med 2001;131:568-70
36. Garcia AM, Busutti RA, Rodriguez A, et al. Detection and analysis of somatic mutations at a lacZ reporter locus in higher organisms: application to Mus musculus and Drosophila melanogaster. Methods Mol Biol 2007;371:267-88
37. Canela A, Klatt P, Blasco MA. Telomere length analysis. Methods Mol Biol 2007;371:45-72 (Pubitemid 350183417)
38. Anisimov SV. Application of DNA microarray technology to gerontological studies. Methods Mol Biol 2007;371:249-66
39. Gart JJ, Krewski D, Lee PN, et al. Statistical Methods in Cancer Research. Volume 3 The Design and Analysis of Long-Term Animal Experiments. IARC Sci Publ No 79; Lyon: 1986
40. Turusov VS, Mohr U. editors. Pathology of Tumours in Laboratory Animals. Volume 1 Tumours of the Rat. 2nd edition. IARC Sci Publ No 99; Lyon: 1990
41. Turusov VS, Mohr U. editors. Pathology of Tumours in Laboratory Animals. Volume 2 Tumours of the Mouse. 2nd
42. edition. IARC Sci Publ No 111; Lyon: 1993
43. Marchuk GI, Anisimov VN, Romanyukha AA, Yashin AI. Gerontology in silico: Establishment of New Discipline. Mathematical Models, Data Analysis and Calculation Experiments. Publ.BINOM; Moskow: 2007
44. Warner HR, Ingram D, Miller RA, et al. Program for testing biological interventions to promote health aging. Mech Ageing Dev 2000;155:199-208
45. Miller RA, Harrison DE, Astle CM, et al. An Aging Intervention Testing Program: stuffy design and interim report. Aging Cell 2007;6:565-75 (Pubitemid 47087061)
46. Miller RA, Nadon NL. Principle of animal use for gerontological research. J Gerontol A Biol Sci Med Sci 2000;55:B117-23 (Pubitemid 30243721)
47. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogenous mice. Nature 2009;460:392-6
48. Vainio H, Magee P, McGregor D, McMichael AJ. editors. Mechanisms of Carcinogenesis in Risk Identification. IARC Sci Publ No 116; Lyon: 1986
49. Korkushko OV, Khavinson VKh, Butenko GM, Shatilo VB. Peptide Preparations of Thymus and Pineal Gland in Prevention of Accelerated Aging. Nauka; St.Petersburg: 2002
50. Zabezhinski MA, Anisimov VN, Popovich IG, et al. Methodology of modern approaches to the evaluation of oncological risk and to reglamentation of chemical carcinogens. In: Merabishvili VM, editor. Oncological Statistics (Tradition Methods, New Information Technology): Manual for Physician. Part II. Publ.Complex KOSTA; St.Petersburg: 2011. p. 175-99
51. !nisimov VN. Carcinogenesis and aging 20 years after: Escaping horizon. Mech Ageing Dev 2009;130:105-21
52. National Toxicology Program. Report on the NTP ad hoc Panel on Chemcal Carcinogenesis Testing and Evaluation. US Department of Health and Human Services; Washington, DC: 1984
53. Solleveld HA, McConneell EE. The value and significance of life span and scheduled termination data in long-term toxicity and carcinogenesis studies. Toxicol Pathol 1985;13:128-34 (Pubitemid 15023329)
54. Stukov AN, Gershanovich ML, Blank MA, et al. Anti-Tumor Drugs. NIKA; St.Petersburg: 2011
55. Anikin IV, Pliss GB, Vlasov NN. Use of autochthonous neoplasia of animals in experimental therapy of tumors. Vopr Onkol 1993;4-6:161-8
56. Amberger H. Different autochthonous models of colorectal cancer in the rat. J Cancer Res Clin Oncol 1986;111:157-9 (Pubitemid 16123995)
57. Meyskens FL, Curt GA, Brenner DE, et al. Chemoprevention Clinical Trials and biomarkers subcommittee regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res 2011;4:311-23
58. Naithani R, Huma LC, Moriarty RM, et al. Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 2008;15:1044-71 (Pubitemid 352005717)
59. Popovich IG, Zabezhinski MA, Anisimov VN. Method of detection of anticarcinogenic activity of drugs in vivo (Guidelines for physicians). Petrov Res. Institute of Oncology Publ; St. Petersburg: 2003
60. Bespalov VG. Cancer chemoprevention. Practical Med 2007;2:73-4
61. Anisimov VN, Ames BN, Arkind R, et al. The 54 Scientists' Open Letter on Aging Research 2006. Available from: http://ieet.org/index.php/IEET/more/ scientistsantiaging/